RAB6A

Across TCGA pan-cancer cohorts, RAB6A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAB6A data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher RAB6A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RAB6A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, LIHC, and UCEC are the cancer types where RAB6A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.273	0.802	.017	15	view →
LIHC	OS	Median	All	0.226	0.773	.008	12	view →
UCEC	DFS	Median	All	1.000	0.635	.026	10	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
BLCA	OS	Median	III,IV	0.229	0.684	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAB6A–ACC (OS)

Open the ACC breakdown →